Developer docs
API playgroundTry for free, no card

Search company profiles

Cerveau Technologies

Full company profile

uuid002aho1

Namestring
Cerveau Technologies
Legal namestring
Cerveau Technologies Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Cerveau Technologies Inc. is a private radiopharmaceutical company founded in 2016 and headquartered in Knoxville, Tennessee, that developed tau PET imaging agents for the diagnostic evaluation of Alzheimer's disease and related neurodegenerative disorders. The company's core technology centered on proprietary radiodiagnostic agents targeting tau tangles, a pathological hallmark of Alzheimer's disease, enabling positron emission tomography (PET) imaging of tau pathology in the brain. Prior to its acquisition, Cerveau operated with a small team of 11-50 employees under President & CEO Rick Hiatt, focused on late-stage R&D and clinical development of its imaging agent portfolio.

The company served the neurology and diagnostic imaging ecosystem, targeting healthcare providers, academic research centers, and PET imaging facilities involved in Alzheimer's disease diagnosis and clinical research. Its business model was pre-commercial, with value creation driven by development of proprietary imaging agents intended for licensing or commercialization through partnerships with larger radiopharmaceutical players. The company's strategic value was anchored in addressing an underserved diagnostic gap in tau pathology imaging, complementing existing amyloid PET diagnostics.

In February 2023, Cerveau Technologies was acquired by Lantheus Holdings Inc., a strategic move that integrated Cerveau's tau PET imaging agent pipeline into Lantheus's broader radiopharmaceutical portfolio. The acquisition provided Cerveau with access to Lantheus's established distribution infrastructure and commercial capabilities, while enabling Lantheus to expand its neurology diagnostics footprint within a PET nuclear medicine market projected to reach $25.7B by 2030 at a 14.3% CAGR.

Short descriptiontext

Cerveau Technologies is a Knoxville-based radiopharmaceutical company that developed tau PET imaging agents for Alzheimer's disease diagnostics. Acquired by Lantheus Holdings in February 2023, it serves neurology and diagnostic imaging providers.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKnoxville, United States
HQ citystring
Knoxville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
Tau PET imaging, Alzheimer's diagnostics, radiopharmaceutical agents, neurological imaging, brain biomarkers
Industry4 codes
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAB
Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Radiopharmaceutical Diagnostics
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cerveau Technologies develops and supplies Tau PET imaging agents—radiodiagnostic tools that target tau tangles, a key biomarker of Alzheimer's disease. Used together with positron emission tomography (PET) imaging modalities, these radiopharmaceuticals enable healthcare providers and researchers to identify disease biomarkers with precision, supporting earlier detection and intervention in neurological disorders.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cerveau Technologies operates as a subsidiary of Lantheus Holdings following its acquisition in February 2023. The company specializes in Tau PET imaging agents designed for Alzheimer's disease diagnostics. These radiopharmaceutical products function as radiodiagnostic tools that, when used in conjunction with PET imaging modalities, enable clinicians to identify tau protein tangles and beta-amyloid plaques—key biomarkers of Alzheimer's disease. The technology supports earlier detection and intervention in neurological disorders.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Eli Lilly markets Tauvid (flortaucipir F18), an FDA-approved tau PET imaging agent for Alzheimer's disease — the closest direct competitor to Cerveau's tau PET tracer, targeting the same biomarker and same neurology imaging customers.

TypeDirect peer
Description

Blue Earth Diagnostics (a Bracco subsidiary) develops and commercializes PET radiopharmaceuticals for diagnostic imaging, including Axumin — a directly comparable specialty radiodiagnostic company serving oncology and neurology imaging centers.

TypeBroad incumbent
Description

Bayer operates a radiopharmaceuticals franchise (including Xofigo and broader oncology imaging) through its pharmaceutical division — a broad incumbent with overlapping radiopharmaceutical manufacturing and distribution capabilities adjacent to Cerveau's diagnostic imaging focus.

TypeBroad incumbent
Description

GE HealthCare markets Vizamyl (flutemetamol F18), an amyloid PET imaging tracer for Alzheimer's disease, and operates broadly across medical imaging, radiopharmaceuticals, and PET equipment — a broad incumbent whose neurology PET franchise directly overlaps Cerveau's diagnostic imaging focus.

TypeBroad incumbent
Description

Bracco Imaging is a global diagnostic imaging company with a portfolio spanning contrast agents and radiopharmaceuticals, and is the parent of Blue Earth Diagnostics — a broad incumbent competing in the same diagnostic imaging space as Cerveau.

TypeDirect peer
Description

Life Molecular Imaging (formerly Piramal Imaging) markets Neuraceq (florbetaben F18), a beta-amyloid PET imaging tracer used in Alzheimer's disease diagnostics — a directly comparable radiodiagnostic imaging agent serving the same neurology diagnostic workflow.

TypeBroad incumbent
Description

Siemens Healthineers is a major medical imaging equipment and diagnostics company, including PET/CT scanners and imaging informatics — a broad incumbent whose installed base of PET scanners and imaging ecosystem directly enables Cerveau's diagnostic imaging use cases.

TypeDirect peer
Description

Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic radiopharmaceuticals, including Illuccix (PSMA-PET imaging), and is expanding into neurology — a directly comparable specialty radiopharma player using PET imaging agents to address disease biomarkers.

TypeDirect peer
Description

Curium is one of the largest nuclear medicine companies globally, manufacturing and distributing PET and SPECT radiopharmaceuticals across multiple therapeutic areas — a directly comparable specialty radiopharmaceutical manufacturer with overlapping customers and distribution channels.

TypeEmerging player
Description

Navidea Biopharmaceuticals develops diagnostic imaging agents, including Lymphoseek and pipeline macrophage-targeted products, focused on molecular imaging biomarkers — an emerging specialty player with a comparable diagnostic radiopharmaceutical development model.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cerveau Technologies

Radiopharmaceutical Diagnosticscerveautechnologies.com

Cerveau Technologies is a Knoxville-based radiopharmaceutical company that developed tau PET imaging agents for Alzheimer's disease diagnostics. Acquired by Lantheus Holdings in February 2023, it serves neurology and diagnostic imaging providers.

What Cerveau Technologies does

Cerveau Technologies Inc. is a private radiopharmaceutical company founded in 2016 and headquartered in Knoxville, Tennessee, that developed tau PET imaging agents for the diagnostic evaluation of Alzheimer's disease and related neurodegenerative disorders. The company's core technology centered on proprietary radiodiagnostic agents targeting tau tangles, a pathological hallmark of Alzheimer's disease, enabling positron emission tomography (PET) imaging of tau pathology in the brain. Prior to its acquisition, Cerveau operated with a small team of 11-50 employees under President & CEO Rick Hiatt, focused on late-stage R&D and clinical development of its imaging agent portfolio.

The company served the neurology and diagnostic imaging ecosystem, targeting healthcare providers, academic research centers, and PET imaging facilities involved in Alzheimer's disease diagnosis and clinical research. Its business model was pre-commercial, with value creation driven by development of proprietary imaging agents intended for licensing or commercialization through partnerships with larger radiopharmaceutical players. The company's strategic value was anchored in addressing an underserved diagnostic gap in tau pathology imaging, complementing existing amyloid PET diagnostics.

In February 2023, Cerveau Technologies was acquired by Lantheus Holdings Inc., a strategic move that integrated Cerveau's tau PET imaging agent pipeline into Lantheus's broader radiopharmaceutical portfolio. The acquisition provided Cerveau with access to Lantheus's established distribution infrastructure and commercial capabilities, while enabling Lantheus to expand its neurology diagnostics footprint within a PET nuclear medicine market projected to reach $25.7B by 2030 at a 14.3% CAGR.

Cerveau Technologies firmographics

Firmographics
Name
Cerveau Technologies
Legal name
Cerveau Technologies Inc.
Website
https://cerveautechnologies.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
11–50 employees
Short description
Cerveau Technologies is a Knoxville-based radiopharmaceutical company that developed tau PET imaging agents for Alzheimer's disease diagnostics. Acquired by Lantheus Holdings in February 2023, it serves neurology and diagnostic imaging providers.
Ownership category
akta.pro rank

Cerveau Technologies industry classification

Industry
Product category
Radiopharmaceutical Diagnostics
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAIAGAA
Diagnostic Radiopharmaceuticals (SPECT/PET Tracers)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAHABAE
Nuclear Medicine & Molecular Imaging (SPECT/PET)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHLAFAKAB
Advanced Imaging & Specialty Radiology Centers (PET/CT, Nuclear Medicine, Interventional Radiology)
SECONDARYHLAKAIAH
Cognitive & Behavioral Neurology (Dementia/Memory Disorders)

Keywords

  • Tau PET imaging
  • Alzheimer's diagnostics
  • Radiopharmaceutical agents
  • Neurological imaging
  • Brain biomarkers

Where Cerveau Technologies is headquartered

Location

Headquarters

HQ city
Knoxville
HQ country
United States
HQ region
North America

Markets served

Cerveau Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Cerveau Technologies product offering

Product offering

Core offering

Cerveau Technologies develops and supplies Tau PET imaging agents—radiodiagnostic tools that target tau tangles, a key biomarker of Alzheimer's disease. Used together with positron emission tomography (PET) imaging modalities, these radiopharmaceuticals enable healthcare providers and researchers to identify disease biomarkers with precision, supporting earlier detection and intervention in neurological disorders.

Product overview

Cerveau Technologies operates as a subsidiary of Lantheus Holdings following its acquisition in February 2023. The company specializes in Tau PET imaging agents designed for Alzheimer's disease diagnostics. These radiopharmaceutical products function as radiodiagnostic tools that, when used in conjunction with PET imaging modalities, enable clinicians to identify tau protein tangles and beta-amyloid plaques—key biomarkers of Alzheimer's disease. The technology supports earlier detection and intervention in neurological disorders.

Differentiator

Problem solved

Functional benefit

Companies that use Cerveau Technologies

Customer profile

Segments1 record

Ideal customer profiles1 record

Cerveau Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Cerveau Technologies partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves1 record

Expansion highlights4 records

Cerveau Technologies competitors and assessment

Company assessment

Direct peers

  • Eli Lilly and Company: Eli Lilly markets Tauvid (flortaucipir F18), an FDA-approved tau PET imaging agent for Alzheimer's disease — the closest direct competitor to Cerveau's tau PET tracer, targeting the same biomarker and same neurology imaging customers.
  • Blue Earth Diagnostics: Blue Earth Diagnostics (a Bracco subsidiary) develops and commercializes PET radiopharmaceuticals for diagnostic imaging, including Axumin — a directly comparable specialty radiodiagnostic company serving oncology and neurology imaging centers.
  • Life Molecular Imaging: Life Molecular Imaging (formerly Piramal Imaging) markets Neuraceq (florbetaben F18), a beta-amyloid PET imaging tracer used in Alzheimer's disease diagnostics — a directly comparable radiodiagnostic imaging agent serving the same neurology diagnostic workflow.
  • Telix Pharmaceuticals: Telix Pharmaceuticals develops and commercializes diagnostic and therapeutic radiopharmaceuticals, including Illuccix (PSMA-PET imaging), and is expanding into neurology — a directly comparable specialty radiopharma player using PET imaging agents to address disease biomarkers.
  • Curium: Curium is one of the largest nuclear medicine companies globally, manufacturing and distributing PET and SPECT radiopharmaceuticals across multiple therapeutic areas — a directly comparable specialty radiopharmaceutical manufacturer with overlapping customers and distribution channels.

Broad incumbents

  • Bayer AG: Bayer operates a radiopharmaceuticals franchise (including Xofigo and broader oncology imaging) through its pharmaceutical division — a broad incumbent with overlapping radiopharmaceutical manufacturing and distribution capabilities adjacent to Cerveau's diagnostic imaging focus.
  • GE HealthCare: GE HealthCare markets Vizamyl (flutemetamol F18), an amyloid PET imaging tracer for Alzheimer's disease, and operates broadly across medical imaging, radiopharmaceuticals, and PET equipment — a broad incumbent whose neurology PET franchise directly overlaps Cerveau's diagnostic imaging focus.
  • Bracco Imaging: Bracco Imaging is a global diagnostic imaging company with a portfolio spanning contrast agents and radiopharmaceuticals, and is the parent of Blue Earth Diagnostics — a broad incumbent competing in the same diagnostic imaging space as Cerveau.
  • Siemens Healthineers: Siemens Healthineers is a major medical imaging equipment and diagnostics company, including PET/CT scanners and imaging informatics — a broad incumbent whose installed base of PET scanners and imaging ecosystem directly enables Cerveau's diagnostic imaging use cases.

Emerging players

  • Navidea Biopharmaceuticals: Navidea Biopharmaceuticals develops diagnostic imaging agents, including Lymphoseek and pipeline macrophage-targeted products, focused on molecular imaging biomarkers — an emerging specialty player with a comparable diagnostic radiopharmaceutical development model.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Cerveau Technologies social profiles

Digital presence

Cerveau Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cerveau Technologies leadership team

Management profile

Number of profiles

Profiles1 record

Cerveau Technologies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cerveau Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cerveau Technologies

What does Cerveau Technologies do?

Cerveau Technologies develops and supplies Tau PET imaging agents—radiodiagnostic tools that target tau tangles, a key biomarker of Alzheimer's disease. Used together with positron emission tomography (PET) imaging modalities, these radiopharmaceuticals enable healthcare providers and researchers to identify disease biomarkers with precision, supporting earlier detection and intervention in neurological disorders.

Is Cerveau Technologies a public or private company?

Cerveau Technologies is a private company. It is classified as corporate owned and is currently acquired.

When was Cerveau Technologies founded?

Cerveau Technologies was founded in 2016. It employs 11 to 50 people.

Where is Cerveau Technologies based?

Cerveau Technologies is headquartered in Knoxville, United States, in the North America region.

Who are Cerveau Technologies's main competitors?

Direct peers on record are Eli Lilly and Company, Blue Earth Diagnostics, Life Molecular Imaging, Telix Pharmaceuticals and Curium. Broad incumbents are Bayer AG, GE HealthCare, Bracco Imaging and Siemens Healthineers. Navidea Biopharmaceuticals is listed as an emerging player.

Does Cerveau Technologies have an API?

No public API is recorded for Cerveau Technologies.

What industry is Cerveau Technologies in?

Cerveau Technologies's product category is Radiopharmaceutical Diagnostics. Its primary akta.pro industry code is HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers), with a secondary code of HLAHABAE, Nuclear Medicine & Molecular Imaging (SPECT/PET). Its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournEnigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s DiseaseEnigma Biomedical USA announced that the U.S. Food and Drug Administration (FDA) has approved TAUKLARIFY, a radiodiagnostic agent for positron emission tomography to identify tau neurofibrillary tangle pathology in patients being evaluated for Alzheimer's disease. The approval follows a collaboration between Enigma Biomedical USA and Lantheus, which acquired the product's subsidiary, Cerveau Technologies, to facilitate its commercialization. Clinical studies involving over 600 subjects demonstrated the agent's efficacy and safety in assessing Alzheimer's status across various stages of cognitive impairment.Business Wire BlogEnigma Biomedical USA Announces FDA Approval of TAUKLARIFY™ (florquinitau F 18 injection) for Use in Patients Being Evaluated for Alzheimer’s DiseaseEnigma Biomedical USA announced that the U.S. Food and Drug Administration (FDA) has approved TAUKLARIFY, a radiodiagnostic agent for use in positron emission tomography (PET) scans to identify tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease. The approval follows a collaboration between Enigma Biomedical USA and Lantheus, which acquired the subsidiary Cerveau Technologies responsible for the product's development. Clinical studies involving 617 subjects demonstrated the efficacy and safety of the imaging agent in assessing tau pathology.PR NewswireDelveInsight Evaluates a Robust Alzheimer's Disease Pipeline as 150+ Influential Pharma Players to Set Foot in the DomainDelveInsight's Alzheimer's disease pipeline report outlines a growing space with over 150 companies developing 160+ pipeline therapies for Alzheimer's disease. In February 2023, Lantheus Holdings acquired Knoxville-based Cerveau Technologies, gaining MK-6240, a second-generation F18-labeled PET imaging agent targeting Tau tangles, under terms including upfront payment, milestone payments, and double-digit royalties. In January 2023, Prothena announced positive Phase I single ascending dose results for PRX005, with all dose cohorts meeting the primary safety objective, while Eli Lilly received a complete response letter from the FDA for accelerated approval of donanemab due to insufficient 12-month drug exposure data, with the confirmatory Phase 3 trial ongoing.AiThorityLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s DiseaseLantheus Holdings has acquired Knoxville-based Cerveau Technologies, Inc., adding the MK-6240 Tau PET imaging agent for Alzheimer’s disease to its diagnostic pipeline. The transaction involves an upfront payment, potential milestone payments, and double-digit royalties, with Lantheus gaining access to extensive academic and pharmaceutical partnerships associated with the asset. This acquisition aligns with Lantheus' strategy to diversify its radiopharmaceutical portfolio and scale operations for future patient care.GlobeNewswireLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s DiseaseLantheus acquired Cerveau Technologies, adding MK-6240, a Tau-targeting PET imaging agent for Alzheimer's disease. The deal includes upfront and milestone payments plus royalties, and Lantheus will provide transition services. The acquisition expands Lantheus's radiopharmaceutical diagnostic pipeline.LantheusLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s DiseaseLantheus Holdings, Inc. has acquired Knoxville-based Cerveau Technologies, Inc., securing the rights to MK-6240, a clinical-stage PET imaging agent targeting Tau tangles in Alzheimer’s disease. The transaction involves an upfront payment, potential milestone payments, and double-digit royalties for Lantheus to expand its diagnostic imaging pipeline. This acquisition integrates MK-6240 into Lantheus' portfolio, leveraging its existing partnerships with over 16 pharmaceutical companies currently using the agent in clinical trials.BenzingaLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer'sLantheus Holdings, Inc. has acquired Cerveau Technologies, Inc., adding the clinical-stage PET imaging agent MK-6240 to its portfolio to expand into Alzheimer's disease diagnostics. This acquisition allows Lantheus to leverage its radiopharmaceutical expertise to advance the development and commercialization of a tracer currently used in over 60 global clinical trials for various therapeutic candidates.GlobeNewswireLantheus Announces Acquisition of Cerveau Technologies, Inc., Expanding Imaging Pipeline into Alzheimer’s DiseaseLantheus Holdings, Inc. has acquired Cerveau Technologies, Inc., securing the rights to MK-6240, a PET imaging agent targeting Tau tangles in Alzheimer’s disease. This transaction expands Lantheus' radiopharmaceutical diagnostic pipeline and integrates Cerveau's technology, which is currently utilized in over 60 clinical trials by more than 16 pharmaceutical companies. The agreement involves upfront payments, potential milestones, and royalty structures, with Cerveau providing transition services post-closing.BioSpaceCerveau Technologies, Inc. and Nihon Med-Physics Co., Ltd. Announce Manufacturing Service Agreement for [18F]MK-6240 in JapanCerveau Technologies and Nihon Medi-Physics signed a manufacturing service agreement granting NMP the right to produce [18F]MK-6240, a PET imaging agent for tau tangles. The collaboration supports clinical studies in Japan from 2022 onward, with six academic institutions already producing the agent.